A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma

This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma.

开始日期2020-07-20

申办/合作机构

Quadriga BioSciences, Inc.初创企业

[+1]

NCT02977780 / Recruiting临床2期IIT

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM).
The drugs involved in this study are :
* Abemaciclib
* Temozolomide (temodar)
* Neratinib
* CC115
* QBS10072S

开始日期2017-02-09

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+5]

100 项与 QBS-10072S 相关的临床结果

登录后查看更多信息

100 项与 QBS-10072S 相关的转化医学

登录后查看更多信息

100 项与 QBS-10072S 相关的专利（医药）

登录后查看更多信息

项与 QBS-10072S 相关的文献（医药）

2024-01-01·Leukemia Research Reports

Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas

Article

作者: Perez-Silos, Vanessa ; Zevallos, Alejandro ; Webb, Shaun ; Rodriguez, Mirna ; Murga-Zamalloa, Carlos ; Fischer, Wolf-Nicolas ; Wilcox, Ryan ; Gao, Guangyao ; Jandeleit, Bernd ; Reneau, John ; Danos-Diaz, Pierina

T-cell lymphomas are aggressive neoplasms characterized by poor responses to current chemotherapeutic agents. Expression of the l-type amino acid transporter 1 (LAT 1, SLC7A5) allows for the expansion of healthy T-cell counterparts, and upregulation of LAT1 has been reported in precursor T-cell acute leukemia. Therefore, the expression of LAT1 was evaluated in a cohort of cutaneous and peripheral T-cell lymphomas. The findings demonstrated that LAT1 is upregulated in aggressive variants and absent in low-grade or indolent disease such as mycosis fungoides. In addition, upregulated LAT1 expression was seen in a large proportion of aggressive peripheral T-cell lymphomas, including peripheral T-cell lymphoma not otherwise specific (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL). The anti-tumor effects of two novel non-cleavable and bifunctional compounds, QBS10072S and QBS10096S, that combine a potent cytotoxic chemotherapeutic domain (tertiary N-bis(2-chloroethyl)amine) with the structural features of a selective LAT1 substrate (aromatic β-amino acid) were tested in vitro and in vivo in T-cell lymphoma cell lines. The findings demonstrated decreased survival of T-cell lymphoma lines with both compounds. Overall, the results demonstrate that LAT1 is a valuable biomarker for aggressive T-cell lymphoma counterparts and QBS10072S and QBS10096S are successful therapeutic options for these aggressive diseases.

2021-11-01·Molecular Cancer Therapeutics2区 · 医学

A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer

2区 · 医学

Article

作者: Chernikova, Sophia B. ; Umeh-Garcia, Maxine C. ; Deng, Jiaojiao ; Koller, Kerry J. ; Ringold, Gordon M. ; Wang, Yuelong ; Gephart, Melanie Hayden ; Rodriguez, Mirna L. ; Ahmadian, Saman S. ; Andersen, Stephanie J. ; Jandeleit, Bernd ; Fischer, Wolf-Nicolas ; Godfrey, Bryanna O.

AbstractDevelopment of metastases to central nervous system (CNS) is an increasing clinical issue following the diagnosis of advanced breast cancer. The propensity to metastasize to CNS varies by breast cancer subtype. Of the four breast cancer subtypes, triple-negative breast cancers (TNBC) have the highest rates of both parenchymal brain metastasis and leptomeningeal metastasis (LM). LM is rapidly fatal due to poor detection and limited therapeutic options. Therapy of TNBC brain metastasis and LM is challenged by multifocal brain metastasis and diffuse spread of LM, and must balance brain penetration, tumor cytotoxicity, and the avoidance of neurotoxicity. Thus, there is an urgent need for novel therapeutic options in TNBCs CNS metastasis. QBS10072S is a novel chemotherapeutic that leverages TNBC-specific defects in DNA repair and LAT1 (L-amino acid transporter type 1)-dependent transport into the brain. In our study, activity of QBS10072S was investigated in vitro with various cell lines including the human TNBC cell line MDA-MB-231 and its brain-tropic derivative MDA-MB-231-BR3. QBS10072S was preferentially toxic to TNBC cells. The efficacy of QBS10072S against brain metastasis and LM was tested using a model of brain metastasis based on the internal carotid injection of luciferase-expressing tumor cells into NuNu mice. The compound was well tolerated, delayed tumor growth and reduced leptomeningeal dissemination, resulting in significant extension of survival. Given that current treatments for LM are palliative with only few studies reporting a survival benefit, QBS10072S is planned to be investigated in clinical trials as a therapeutic for TNBC LM.Significance:TNBC brain metastasis often involves dissemination into leptomeninges. Treatment options for TNBC leptomeningeal metastasis are limited and are mostly palliative. Our study demonstrates significant efficacy of the brain-penetrating agent QBS10072S against TNBC brain metastasis and leptomeningeal spread.

2021-08-31·Cureus

A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma

Article

作者: Nicolaides, Theodore ; Rodriguez, Mirna ; Zhao, Guisheng ; Ozawa, Tomoko ; Fischer, Wolf-Nicolas ; Koller, Kerry ; Yao, Tsun Wen ; Jandeleit, Bernd

Introduction The standard treatment for glioblastoma (GBM) patients is surgical tumor resection, followed by radiation and chemotherapy with temozolomide (TMZ). Unfortunately, 60% of newly diagnosed GBM patients express high levels of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) and are TMZ-resistant, and all patients eventually become refractory to treatment. The blood-brain barrier (BBB) is an obstacle to the delivery of chemotherapeutic agents to GBM, and BBB-permeable agents that are efficacious in TMZ-resistant and refractory patients are needed. The large amino acid transporter 1 (LAT1) is expressed on the BBB and in GBM and is detected at much lower levels in normal brain tissue. A LAT1-selective therapeutic would potentially target brain tumors while avoiding uptake by healthy tissue. Methods We report a novel chemical entity (QBS10072S) that combines a potent cytotoxic chemotherapeutic domain (tertiary N-bis(2-chloroethyl)amine) with the structural features of a selective LAT1 substrate and tested it against GBM models in vitro and in vivo. For in vitro studies, DNA damage was assessed with a gamma H2A.X antibody and cell viability was assessed by WST-1 assay and/or CellTiter-Glo assay. For in vivo studies, QBS10072S (with or without radiation) was tested in orthotopic glioblastoma xenograft models, using overall survival and tumor size (as measured by bioluminescence), as endpoints. Results QBS10072S is 50-fold more selective for LAT1 vs. LAT2 in transport assays and demonstrates significant growth suppression in vitro of LAT1-expressing GBM cell lines. Unlike TMZ, QBS10072S is cytotoxic to cells with both high and low levels of MGMT expression. In orthotopic GBM xenografts, QBS10072S treatment significantly delayed tumorigenesis and prolonged animal survival compared to the vehicle without adverse effects. Conclusion QBS10072S is a novel BBB-permeable chemotherapeutic agent with the potential to treat TMZ-resistant and recurrent GBM as monotherapy or in combination with radiation treatment.

项与 QBS-10072S 相关的新闻（医药）

2023-04-13

·SYNAPSE

SMDC药物QBS10072S Ⅱ期临床开展，完成首例给药

4月12日，Quadriga BioSciences宣布，其针对性治疗癌症的自研药品QBS10072S（QBS72S）的首位Ⅱ期研究受试者已经入院，以评估其用于乳腺癌的脑转移治疗的有效性。乳腺癌常被称为“粉红杀手”，其发病率位居女性恶性肿瘤的首位。据2018年国际癌症研究机构（IARC）调查的最新数据显示，乳腺癌在全球女性癌症中的发病率为24.2%，位居女性癌症的首位，其中52.9%发生在发展中国家。在容易发生脑转移的癌症中，乳腺癌仅次于肺癌，排在第二位，其中又以HER2阳性乳腺癌或者三阴性乳腺癌发生脑转移最为常见。乳腺癌发生脑转移，说明已经处于晚期，预后较差。目前尚无乳腺癌脑转移的治愈手段，一般采取积极治疗，包括化疗、内分泌治疗和生物治疗等全身综合治疗。小分子偶联药物（SMDC）是由小分子的靶向配体与细胞毒药物偶联所得，由三部分构成：小分子靶向配体、细胞毒分子和连接子。与ADC（抗体偶联药物）相比，SMDC能更快速均匀地分散到肿瘤组织中，且成本低、无免疫原性。与体积较大的ADC 相比，小分子配体未与受体结合的SMDC 更能快速地从体内排泄，避免长时间血液循环导致细胞毒药物释放引起的不良反应；此外，由于SMDC所用的连接基一般是可断裂的，能够在几分钟至1 h 内快速地与受体结合及被肾脏清除，因此SMDC 对连接基的稳定性要求与需要在血液中循环较长时间的ADC 相比较低，一般只要求能保持几分钟至1 h 的稳定性。大多数乳腺癌的治疗方法在脑转移时有效性有限，部分原因是目前的化疗药物无法以足够的浓度穿过血脑屏障。QBS72S是Quadriga开发的一款靶向LAT1的全球首创新型双功能小分子偶联药物。该在研药经由LAT1高效、主动地透过血脑屏障转运至大脑，并选择性地进入LAT1高表达的肿瘤细胞，同时也使得通常不表达LAT1的正常组织免受损伤。在肿瘤细胞内，QBS72S通过干扰快速分裂的肿瘤细胞的DNA复制发挥其细胞杀伤活性，从而杀死肿瘤。本次开展的Ⅱ期开放标签临床试验旨在评估QBS72S对乳腺癌脑转移患者的安全性、耐受性和疗效。该研究将招募多达35名患者，主要终点是通过总反应率确定初步疗效。次要终点包括测量无进展生存期、总生存期、反应时间和不良事件。此外，在Dana-Farber癌症研究所进行的INSIGhT Ⅱ期研究中，QBS72S也正在作为潜在的胶质母细胞瘤治疗方法进行评估。这两个Ⅱ期研究都获得了小企业创新研究基金（SBIR）的资助。乳腺癌的研究得到了加利福尼亚乳腺癌研究计划的支持。 Quadriga BioSciences首席执行官Gordon Ringold博士表示：“在肿瘤学领域，脑转移的治疗是一个重要的未满足需求，因为目前尚未批准任何治疗方案。QBS72S具有通过血脑屏障，针对癌细胞的能力，有望改善这些患者的疗效。我们期待与斯坦福医学的同事们更近一步地开展调查。” 斯坦福医学的神经外科教授、斯坦福脑瘤中心联合主任、Ⅱ期临床研究的首席研究员Melanie Hayden Gephart博士表示，“乳腺癌是最常见的转移至大脑的肿瘤之一。乳腺癌脑转移会恶化预后，对生活质量产生负面影响，目前可用的治疗手段有限。QBS72S在临床前研究中已显示出治疗希望，因为其具有针对性的作用机制。我期待这个药物能够为有需要的患者带来帮助。” 参考资料： https://www.quadrigabiosciences.com/wp-content/uploads/2023/04/Quadriga-First-Patient-In-Stanford-Study-FINAL.pdf

小分子药物临床研究

2023-04-11

·PRNewswire

Quadriga BioSciences Announces Dosing of First Subject in Phase 2 Study Evaluating QBS72S For Brain Metastases of Breast Cancer

LOS ALTOS, Calif., April 11, 2023 /PRNewswire/ -- Quadriga BioSciences, a clinical-stage oncology company developing QBS10072S (QBS72S) for the targeted treatment of cancer, today announced the dosing of the first subject in a Phase 2 study evaluating QBS72S for the treatment of brain metastases of breast cancers. "The treatment of brain metastases is a significant unmet need in oncology, as no approved therapies exist," said Gordon Ringold, Ph.D., Chief Executive Officer of Quadriga BioSciences. "With its ability to cross the blood brain barrier and target cancer cells, QBS72S has the potential to improve outcomes in these patients. We look forward to investigating this more closely with our colleagues at Stanford Medicine." Most therapies for breast cancer have limited efficacy when metastasized to the brain, due in part to the inability for current chemotherapeutics to cross the blood brain barrier (BBB) in sufficient concentrations. "Breast cancer is one of the most common tumors to metastasize to the brain. Breast cancer brain metastases worsen prognosis, negatively affect quality of life, and currently available treatments are limited," said Melanie Hayden Gephart, M.D., Professor of Neurosurgery at Stanford Medicine, co-director of the Stanford Brain Tumor Center, and Principal Investigator of the Phase 2 clinical study. "QBS72S has shown promise in preclinical studies due to its targeted mechanism of action. I look forward to the opportunity to investigate this compound for patients in need." QBS72S is also being investigated as a potential glioblastoma treatment in the Phase 2 INSIGhT study at the Dana-Farber Cancer Institute (find more information here). The two Phase 2 studies are each funded by Small Business Innovation Grants (SBIR). The breast cancer study received initial support from the California Breast Cancer Research Program. About QBS72S QBS72S is a novel, first-in-class chemotherapeutic agent that mimics an aromatic amino acid for cellular uptake by the amino acid transporter LAT1 (L-type amino acid transporter 1) thereby enabling the drug to cross the blood brain barrier (BBB) as well as to selectively target numerous types of rapidly growing cancer cells. Once inside the cell QBS72S causes double-stranded DNA breaks resulting in cell death. Most aggressive cancers express high LAT1, which is commonly associated with poor prognoses.1 About the Study The Phase 2 open-label clinical trial is designed to assess the safety, tolerability and efficacy of QBS72S in patients with brain metastases from breast cancer. The study will recruit up to 35 patients with the primary objective of determining preliminary efficacy through overall response rate. Secondary endpoints include measurement of progression free survival, overall survival, duration of response, and adverse events. Please refer to [NCT05305365] for additional clinical trial details. About Quadriga BioSciences Quadriga BioSciences is a clinical-stage oncology company developing QBS10072S (QBS72S), a novel, first-in-class chemotherapeutic agent that exploits the amino acid transporter LAT1, enabling the drug to cross the blood brain barrier (BBB) as well as to selectively target numerous types of rapidly growing cancer cells. Our technology is based on the discovery that many aggressive forms cancer cells overexpress LAT1 on their cell surfaces for the intake of nutrients to support rapid tumor growth and proliferation. Our mission is to develop safer and more effective treatments for patients with cancer. For more information, please visit . Contact Information General Inquiries [email protected] +1 (650) 917 9098 Media Inquiries David Melamed, Ph.D. [email protected] +1 (212) 845-4225 SOURCE Quadriga BioSciences, Inc.

临床2期

2022-12-10

·医药观澜

阿斯利康、友芝友生物、本草八达、必贝特医药等公司1类新药获批临床丨CDE周报

▎药明康德内容团队编辑根据中国国家药监局药品审评中心（CDE）官网数据，本周有多款1类新药临床试验申请通过“默示许可”。这些产品包括了靶向LAT1的双功能小分子药物、KRAS G12C抑制剂、抗PD-1/TIM-3双特异性抗体、基因替代疗法、CD20/CD3双抗等，拟开发适应症包括肿瘤、痛风、致盲性遗传性眼病等。本文将挑选其中部分1类新药作介绍，供读者参阅（排名不分先后）。图片来源：123RF本草八达：NBQ72S作用机制：靶向LAT1的双功能小分子药物适应症：晚期转移性实体瘤（包括实体瘤脑转移）公开资料显示，本草八达由本草资本运营孵化，是一家致力于攻克脑部肿瘤的临床阶段生物医药公司。NBQ72S（又称QBS10072S）是一款潜在“first-in-class”靶向人L型氨基酸转运蛋白1（LAT1）的新型双功能小分子药物，拟开发治疗脑部肿瘤等恶性肿瘤。LAT1是溶质转运蛋白（SLC）超家族成员，通常高表达于血脑屏障，并且在大多数侵袭性恶性肿瘤中也有极高的表达，例如多形性胶质母细胞瘤（GBM）、乳腺癌、肺癌和黑色素瘤等。据本草八达早先新闻稿介绍，NBQ72S经由LAT1高效、主动地透过血脑屏障转运至大脑，并选择性地进入LAT1高表达的肿瘤细胞，同时也使得通常不表达LAT1的正常组织免受损伤。在肿瘤细胞内，NBQ72S通过干扰快速分裂的肿瘤细胞的DNA复制发挥其细胞杀伤活性，从而杀死肿瘤。临床前研究表明NBQ72S能够有效地透过血脑屏障并富集于脑部肿瘤。根据ClinicalTrials官网，NBQ72S正在美国开展治疗三阴性乳腺癌脑转移的2期临床研究。本次该药在中国获批临床，针对适应症为晚期转移性实体瘤（包括实体瘤脑转移）。友芝友生物：Y101D作用机制：抗PD-L1和抗TGF-β双特异性抗体适应症：晚期或转移性胰腺癌根据友芝友生物公开资料，Y101D是一种重组抗PD-L1和抗TGF-β人源化双特异性抗体，拟用于治疗胰腺癌、肝细胞癌和其它晚期实体瘤。该产品专门用于同时抑制PD-1/PD-L1轴和TGF-β信号通路，因此具有释放协同抗肿瘤活性和缓解耐药性的潜力。就在昨日，友芝友生物向港交所递交IPO申请。根据友芝友生物招股书，Y101D已经在开展针对转移性或局部晚期实体瘤的1期临床试验。本次Y101D获批临床的适应症为晚期或转移性胰腺癌。LG CHEM：tigulixostat片作用机制：黄嘌呤氧化酶抑制剂适应症：痛风根据LG CHEM公司公开资料，tigulixostat是一种每日一次的口服药物。它可抑制黄嘌呤氧化酶的酶活性，从而减少尿酸的产生，后者是痛风的主要原因。在2期临床研究中，该药显示出高效、快速降低尿酸的效果，有望成为一种新型痛风药物。LG CHEM于今年8月宣布向FDA递交该药的全球3期临床研究申请（EURELIA_1研究和EURELIA_2研究）。据悉，3期临床研究将针对约3000名痛风患者展开，评估该药分别与安慰剂、别嘌呤醇对比，治疗伴有高尿酸血症的成年痛风患者的有效性和安全性。本次，tigulixostat在中国获批临床，针对适应症为痛风。图片来源：123RF必贝特医药：BEBT-607片作用机制：KRAS G12C抑制剂适应症：伴有KRAS G12C突变的晚期或转移性实体瘤根据必贝特医药官网介绍，BEBT-607是一种高活性KRAS G12C抑制剂，拟开发单药和联合用药用于治疗KRAS G12C突变的非小细胞肺癌、结直肠癌、胰腺癌等实体瘤。BEBT-607结构新颖，具有对靶点抑制活性较强、口服暴露量高、抑制肿瘤生长作用好等特点。临床前动物模型研究表明，BEBT-607在KRAS G12C突变肿瘤模型中可使肿瘤消失。本次该药在中国获批临床，拟开发适应症为伴有KRAS G12C突变的晚期或转移性实体瘤。阿斯利康（AstraZeneca）：AZD7789作用机制：抗PD-1/TIM-3双特异性抗体适应症：非小细胞肺癌公开资料显示，AZD7789是阿斯利康在研管线中的一款抗PD-1/TIM-3双特异性抗体。PD-1是程序性细胞死亡受体，PD-1/PD-L1信号通路在肿瘤免疫的逃逸中扮演着重要角色。TIM-3是一种负调控的免疫检查点，存在于不同类型的免疫细胞中。TIM-3信号通路在T细胞活性和数量的调节上起着重要作用，可通过介导细胞凋亡而参与肿瘤的免疫抑制及其发生进展。TIM-3受体多在免疫细胞和髓系白血病细胞表面表达，其水平与急性髓系白血病和骨髓增生异常综合症的严重程度相关。根据阿斯利康官网信息，AZD7789拟开发治疗实体瘤和血液系统恶性肿瘤，并正在海外开展针对晚期或转移性实体瘤的1/2期临床研究。本次，该药在中国获批临床的适应症为非小细胞肺癌。中因科技：ZVS101e注射液作用机制：基因替代疗法适应症：结晶样视网膜变性结晶样视网膜变性（BCD）是一种遗传性视网膜退行性疾病，典型改变为黄白色闪光结晶样物质沉积于视网膜，伴有视网膜色素上皮细胞和脉络膜毛细血管层萎缩。CYP4V2已被鉴定为BCD的致病基因。公开资料显示，绝大多数BCD患者20～40岁发病，双眼受累，早期可能无症状，随着疾病进展，出现视力下降、视野缩小、夜盲症和色觉障碍等症状，患者通常在50～60岁时由于严重的视力下降和视野缩小成为法定盲人。BCD患者目前仍缺乏有效的临床治疗手段。根据中因科技新闻稿，ZVS101e注射液是一款基因替代疗法药物，含表达人CYP4V2蛋白的重组AAV血清型8（rAAV8）载体（rAAV8-hCYP4V2）。ZVS101e所含治疗载体对视网膜细胞有特殊嗜性，注射入患者视网膜下腔后，可高效感染视网膜的视网膜色素上皮细胞（RPE），并在RPE细胞中特异性表达CYP4V2蛋白，弥补由于基因突变导致的蛋白功能缺失，从而对BCD患者的视网膜功能恢复起到有效治疗作用。据介绍，该替代治疗药物将适用于所有携带CYP4V2基因突变的BCD患者。本次，该药在中国获批临床的适应症为结晶样视网膜变性（携带CYP4V2双等位基因突变）。图片来源：123RF天广实生物：注射用MBS303作用机制：CD20/CD3双抗适应症：CD20阳性的B细胞淋巴瘤根据天广实生物公开资料，MBS303是该公司自主研发的一款CD20/CD3 T细胞重定向双特异性抗体，本次获批的是一项治疗复发/难治性CD20阳性B细胞非霍奇金淋巴瘤（B-NHL）的1/2期临床试验。CD20是经临床验证的治疗靶点，在许多B细胞恶性肿瘤上表达，包括弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤和慢性淋巴细胞白血病等。据天广实生物公开资料介绍，MBS303是一款2:1结构CD20/CD3双特异性抗体。通过两个结合臂与肿瘤细胞上的CD20结合，一个结合臂与T细胞上的CD3结合，MBS303增加了与肿瘤细胞的亲和力，诱导T细胞激活并减少脱靶毒性。同时天广实生物的设计使得MBS303的scFv稳定性得到增强，具有更好的成药性。此外，MBS303的特殊抗体结构设计可以在细胞比例较低的情况下，也能产生对肿瘤细胞较强的结合活性和杀伤活性，并对T细胞的亲和力以及激活相对可控。盛世泰科：CGT-1967作用机制：CDK4/6抑制剂适应症：急性髓系白血病根据盛世泰科新闻稿，CGT-1967是一款在研的CDK4/6抑制剂，拟开发用于治疗血液癌。CDK4/6即细胞周期蛋白依赖性激酶4和6，是人体细胞分裂增殖周期的关键条件蛋白，可触发细胞周期从生长期向DNA复制期转变。CDK4/6在很多恶性肿瘤中过度活跃，促使癌细胞增殖扩散，而CDK4/6抑制剂则可将细胞周期阻滞于生长期，从而发挥抑制肿瘤细胞增殖的作用。据盛世泰科新闻稿介绍，CGT-1967在临床前的开发过程中利用公司PD2（精准化抗癌药物开发）平台，在小鼠模型研究中可以显著抑制肿瘤细胞在血液、脾脏和骨髓占位，延长动物生存期。盛世泰科差异化地选择将该药用于急性髓系白血病（AML）患者的治疗。本次，CGT-1967在中国获批临床的适应症为血液系统恶性疾病（急性髓系白血病）。参考资料：[1]中国国家药监局药品审评中心（CDE）官网.Retrieved Dec 9，2022, From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c[2]各公司官网及公开资料本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

IPO临床2期临床1期申请上市临床申请

100 项与 QBS-10072S 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑转移瘤	临床2期	美国	Stanford University	2022-08-16
脑转移瘤	临床2期	美国	Quadriga BioSciences, Inc.初创企业	2022-08-16
乳腺癌	临床2期	美国	Stanford University	2022-08-16
乳腺癌	临床2期	美国	Quadriga BioSciences, Inc.初创企业	2022-08-16
脑膜肿瘤	临床2期	美国	Stanford University	2022-08-16
脑膜肿瘤	临床2期	美国	Quadriga BioSciences, Inc.初创企业	2022-08-16
胶质母细胞瘤	临床2期	美国	Quadriga BioSciences, Inc.初创企业	2017-02-09
胶质母细胞瘤	临床2期	美国	Puma Biotechnology, Inc.	2017-02-09
胶质母细胞瘤	临床2期	美国	Eli Lilly & Co.	2017-02-09
胶质母细胞瘤	临床2期	美国	Celgene Corp.	2017-02-09